Featured Articles

1. Understanding FDA's Plausible Mechanism Framework For Genetic Medicines 6/19/2026

   FDA’s draft “plausible mechanism” framework gives individualized genetic therapies a clearer path to market, but questions remain, write experts at Morrison Foerster.

2. Future Patients: Why Procurement Matters In Emerging Life Sciences 6/16/2026

   As emerging biotechs scale, procurement is becoming a key lever for patient access, resilience, and long-term commercial success.

3. The Fatal Flaw In Pharma's Multi-Million Supply Chain Tech Upgrades 6/12/2026

   AI tools improve visibility, but pharma supply chains stay fragile when leaders favor cost and efficiency over diversification, redundancy, and long-term resilience.

4. From Clinical To Market: Managing Pharma's Most Challenging Transition 6/10/2026

   For drugmakers, approval is just the opening bell; the challenge is turning scientific success into commercial traction, writes ARS Pharmaceutical CEO Richard Lowenthal.

5. How Small And Midsize Pharma Companies Can Fight Drug Diversion 6/8/2026

   Illegal online pharmacies cost biopharma billions and put lives at risk. Small and midsize companies must move fast to safeguard patients and protect product integrity.

6. Five Ways To Unleash The Potential Of Women In STEM 6/5/2026

   Women earn STEM degrees at high rates but remain underrepresented in STEM jobs and leadership. A biotech exec outlines five ways to close the gap.

7. Five Reasons The Hub-And-Spoke Model Is Gaining Traction In Biotech 6/3/2026

   Biotech is shifting to hub-and-spoke models to share infrastructure, reduce single-asset risk, and build repeatable engines for innovation.

8. Why Drug Repurposing Might Be Biotech's Most Capital-Efficient Strategy 5/29/2026

   In a tighter capital environment, drug repurposing offers biotech a more disciplined path to clinical progress and operational efficiency, writes Paul Michaels. 

9. The Bond Factor: Relationship-Driven Performance 5/27/2026

   Trust-driven relationships, not strategy alone, power performance, helping leaders drive change, collaboration, and resilience, writes Wanda Shoer.

10. Patient Data Now Has Borders. Does Your Life Sciences Strategy? 5/22/2026

    As patient data rules tighten globally, life sciences companies should treat data sovereignty as a strategic opportunity to improve trial operations and partnerships.